[Treatment of alcoholic toxic fatty liver. A placebo-controlled trial with hepavis (author's transl)].
A placebo-controlled double-blind study of 30 patients with advanced chronic fatty liver was intended to show how far treatment with a liver preparation, in this case Hepavis, is superior to alcohol abstinence alone. Examination of the laboratory parameters, especially of gamma GT shows that treatment with Hepavis with simultaneous withdrawal of alcohol produces a rapid normalization or improvement of the laboratory findings and consequently an accelerated improvement in the course of the disease. This leads to the conclusion that the pathological activity of the liver cell is reduced more quickly by the constituents of Hepavis than without suitable therapy, and that a more favorable prognosis for the fatty liver as a potential precurser of cirrhosis is to be attained. Not only is elimination of the lipogenic factor, alcohol, essential in the treatment of fatty liver, but also treatment with hepatotropic substances.
D000328:Adult; D002794:Choline / Q000627:therapeutic use*; D003685:Dehydrocholic Acid / Q000627:therapeutic use*; D004338:Drug Combinations; D004341:Drug Evaluation; D005235:Fatty Liver, Alcoholic / Q000188:drug therapy*; D005260:Female; D006801:Humans; D008274:Magnesium / Q000627:therapeutic use; D008297:Male; D009963:Orotic Acid / Q000627:therapeutic use*; D014805:Vitamin B 12 / Q000627:therapeutic use*
D004338:Drug Combinations; D009963:Orotic Acid; D008274:Magnesium; D002794:Choline; D003685:Dehydrocholic Acid; D014805:Vitamin B 12
Therapie der alkohol-toxischen Fettleber. Plazebo-kontrollierte Doppelblindstudie mit Hepavis.